CDC Offers Guidance on 2 vs. 3 Doses of Serogroup B Meningococcal Vaccine — Physician’s First Watch
CDC Offers Guidance on 2 vs. 3 Doses of Serogroup B Meningococcal Vaccine
By Kelly Young
The CDC has published new recommendations on when to use two or three doses of the MenB-FHbp vaccine (Trumenba) for preventing serogroup B meningococcal disease.
For patients aged 10 to 25 years who are at increased risk for meningococcal disease (e.g., patients with persistent complement component deficiencies or anatomic or functional asplenia, or microbiologists exposed to N. meningitidis), three doses of MenB-FHbp can be given at 0, 1–2, and 6 months. The three-dose series is also recommended during outbreaks of meningococcal disease. (Category A recommendation)
For patients aged 16 to 23 who aren't at increased risk, two doses of the vaccine should be given at 0 and 6 months. (Category B recommendation)
The recommendations, published in MMWR, don't apply to the other serogroup B meningococcal vaccine, known as MenB-4C (Bexsero). The agency doesn't specify a preference of one vaccine over the other, but patients should stick to one type of vaccine for the series. MenB vaccines can be given with other vaccines, but they should be administered at a different anatomic location.